Erlotinib Hydrochloride: A Comprehensive Introduction
Erlotinib Hydrochloride (CAS 183319-69-9) is a well – known and highly significant compound in the field of pharmaceuticals. This article aims to provide a detailed overview of Erlotinib Hydrochloride, including its properties, uses, applications in various fields, and preparation methods.
Properties of Erlotinib Hydrochloride
Erlotinib Hydrochloride is a white to off – white powder. Chemically, it is the hydrochloride salt of erlotinib, which is a quinazoline – based compound. Its molecular formula is C₂₂H₂₃N₃O₄ • HCl, and it has a molecular weight of approximately 429.9 g/mol. The compound is sparingly soluble in water, with a solubility that can be affected by factors such as pH and temperature. It is also soluble in some organic solvents, which is an important characteristic for its formulation and processing.
From a physical and chemical stability perspective, Erlotinib Hydrochloride should be stored under specific conditions to maintain its integrity. It is sensitive to light and moisture, and improper storage can lead to degradation, which may affect its efficacy and safety. Therefore, it is typically stored in a cool, dry place, protected from light, in tightly sealed containers.
Uses of Erlotinib Hydrochloride
One of the primary uses of Erlotinib Hydrochloride is in the treatment of cancer. It acts as a tyrosine kinase inhibitor, specifically targeting the epidermal growth factor receptor (EGFR). By inhibiting the tyrosine kinase activity of EGFR, Erlotinib Hydrochloride can block the signaling pathways that are crucial for tumor cell growth, proliferation, survival, and angiogenesis. This mechanism of action makes it an effective therapeutic agent for certain types of cancer.
In non – small cell lung cancer (NSCLC), Erlotinib Hydrochloride has shown significant clinical benefits. It is often used as a first – line treatment for patients with EGFR – activating mutations. Clinical trials have demonstrated that patients treated with Erlotinib Hydrochloride experience longer progression – free survival compared to those receiving traditional chemotherapy. Additionally, it can also be used in the second – or third – line treatment of NSCLC, providing an alternative option for patients who have failed previous treatments.
Another important use is in the treatment of pancreatic cancer. When combined with gemcitabine, Erlotinib Hydrochloride has been approved for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer. The combination therapy has been shown to improve overall survival and quality of life in patients with this type of cancer.
Applications in Various Fields
Medical Field
In addition to its well – established use in cancer treatment, Erlotinib Hydrochloride is also being investigated for its potential in other medical areas. Some research is exploring its role in the treatment of other types of solid tumors, such as head and neck cancer. The compound’s ability to target specific signaling pathways makes it a promising candidate for personalized medicine, where treatment can be tailored to the genetic profile of the patient.
Research Field
Erlotinib Hydrochloride is widely used in cancer research laboratories. It serves as a valuable tool for studying the EGFR signaling pathway and its role in tumorigenesis. Researchers use it to understand the molecular mechanisms underlying cancer development and progression, as well as to screen for new drugs and therapeutic targets. By using Erlotinib Hydrochloride in in vitro and in vivo experiments, scientists can gain insights into how to develop more effective cancer treatments.
Pharmaceutical Industry
In the pharmaceutical industry, Erlotinib Hydrochloride is an important active pharmaceutical ingredient (API). Pharmaceutical companies are involved in the development, production, and marketing of Erlotinib Hydrochloride – based drugs. They need to ensure strict quality control during the manufacturing process to meet regulatory requirements. The formulation of Erlotinib Hydrochloride into tablets or other dosage forms also requires careful consideration of factors such as bioavailability, stability, and patient compliance.
Preparation Methods of Erlotinib Hydrochloride
The synthesis of Erlotinib Hydrochloride typically involves multiple steps. One common approach starts with the synthesis of the quinazoline core structure. This can be achieved through a series of chemical reactions, including condensation reactions and cyclization reactions. For example, starting materials such as anilines and formic acid derivatives can be used to form the basic quinazoline ring system.
After the formation of the quinazoline core, further functionalization steps are carried out to introduce the necessary substituents. This may involve reactions such as alkylation, acylation, and amination. The final step is the formation of the hydrochloride salt. This is usually done by reacting the free base of erlotinib with hydrochloric acid in an appropriate solvent system. The reaction conditions, such as temperature, reaction time, and the ratio of reactants, need to be carefully controlled to ensure high – yield and high – purity product.
Another method for the preparation of Erlotinib Hydrochloride may involve the use of different starting materials and reaction sequences. However, regardless of the specific method, the key is to ensure the formation of the correct chemical structure and the proper purification of the final product to meet the quality standards required for pharmaceutical use.
Send InquiryReferences
- Author1. “Title of Article 1”. Journal Name 1, Volume, Pages (Year).
- Author2. “Title of Article 2”. Journal Name 2, Volume, Pages (Year).